Medicus pharma ltd. provides update on doxorubicin containing novel microneedle array (d-mna) clinical development program for the treatment of basal cell carcinoma (bcc) of the skin and reports second quarter 2025 financial highlights

Us food and drug administration (fda) has accepted the company's type c meeting request and sknjct-003 phase 2 study has randomized more than 75% of patients philadelphia, pennsylvania--(newsfile corp. - august 21, 2025) - medicus pharma ltd. (nasdaq: mdcx) ("medicus" or the "company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, is pleased to announce, following the acceptance of the type c meeting request by the united states food and drug administration (the "fda"), the company has submitted its queries in writing and expect to receive a response from the fda before the end of q3 2025.
BCC Ratings Summary
BCC Quant Ranking